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Abstract A new methodological framework for assessing
agreement between cost-effectiveness endpoints generated
using alternative sources of data on treatment costs and
effects for trial-based economic evaluations is proposed.
The framework can be used to validate cost-effectiveness
endpoints generated from routine data sources when com-
parable data is available directly from trial case report
forms or from another source. We illustrate application of
the framework using data from a recent trial-based eco-
nomic evaluation of the probiotic Bifidobacterium breve
strain BBG administered to babies less than 31 weeks of
gestation. Cost-effectiveness endpoints are compared using
two sources of information; trial case report forms and data
extracted from the National Neonatal Research Database
(NNRD), a clinical database created through collaborative
efforts of UK neonatal services. Focusing on mean incre-
mental net benefits at £30,000 per episode of sepsis aver-
ted, the study revealed no evidence of discrepancy between
the data sources (two-sided p values[0.4), low probability
estimates of miscoverage (ranging from 0.039 to 0.060)
and concordance correlation coefficients greater than 0.86.
We conclude that the NNRD could potentially serve as a
reliable source of data for future trial-based economic
evaluations of neonatal interventions. We also discuss the
potential implications of increasing opportunity to utilize
routinely available data for the conduct of trial-based
economic evaluations.
Keywords Agreement  Cost-effectiveness analysis 
Economic evaluation  Routine data  Electronic health
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JEL Classification I
Introduction
In trial-based economic evaluations, data on treatment
costs and consequences (effects) are required for trial
participants with the aim of estimating the relative cost-
effectiveness of two or more interventions. It is common
practice within this context for multiple sources of infor-
mation to be obtained by analysts and used to inform the
evaluation. For example, data on healthcare resource use
and costs can normally be obtained from a variety of
sources including trial case report forms, medical records,
patient questionnaires, and diaries [26]. With the advent of
the ‘big data’ revolution, large volumes of individual-level
information are being collected prospectively from patients
and stored in administrative datasets and electronic health
record systems. These routinely collected datasets consti-
tute a rich source of information for health research—they
are increasingly being relied upon as sources of informa-
tion for trial-based economic evaluations and health tech-
nology assessments. For example, data drawn from the
Hospital Episode Statistics (HES) in the UK have been
obtained for use in the CAP trial to evaluate the clinical
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and cost-effectiveness of prostate-specific antigen testing
in men aged 50–69 years old [36, 37]. Furthermore, in a
recently published editorial in the British Medical Journal
on reforms of the UK Cancer Drug Fund, Grieve et al. [13]
suggested ‘‘using timely randomized controlled trials
within routinely collected data sources, to establish which
drugs are relatively effective’’ and cost-effective.
It is likely that use of routine data in trial-based eco-
nomic evaluations will increase in the coming years in the
UK context and beyond. This is largely driven by increased
access to datasets and advances in computerized record
linkage that enable datasets to be linked with each other
[29] and increasingly to trial participants at the individual
patient-level. Linkage to trial participants is crucial in this
context as the within-trial randomization can be relied upon
to generate unbiased estimates of treatment impacts based
on information contained in the routine data sources. That
being said, what is not known is whether routine data
sources can provide reliable information across the broad
array of data required for trial-based economic evaluations
[36]. This is because the datasets have generally been
compiled for non-research purposes, such as the need to
evaluate health service performance or monitor care
delivery, and hence may not adequately satisfy the rigors
required of clinical trial research. Consequently, there are
often concerns about data quality, including missing
information, incomplete coding, and miss-classification of
variables—issues that have potential to render the data
unsuitable for most clinical research.
For the reasons stated above, analysts working on trial-
based economic evaluations have long recognized the need
for validated data obtained from disparate sources for
application within their evaluations [4]. In this context,
analysts have examined the disparate sources of informa-
tion for evidence of difference [36] or agreement
[4, 15, 21, 23, 31] in individual parameter estimates. These
studies have primarily focused on comparisons between
multiple sources of information on individual-level
healthcare resource use or costs.
In this paper, we outline a new methodological frame-
work for assessing agreement between the final cost-ef-
fectiveness endpoints generated using alternative sources
of data on treatment costs and effects for trial-based eco-
nomic evaluations. The proposed framework builds on the
earlier work of Bland and Altman [1, 3] and Lin [18] on
methods for assessing the reproducibility of clinical assays,
measurements, and tests. The framework can be used to
validate estimates of cost-effectiveness endpoints gener-
ated using routine data sources when comparable data on
costs and effects for trial participants are available from a
de novo data source, such as trial case report forms.
Of the two most commonly reported endpoints in eco-
nomic evaluations, namely the incremental cost-
effectiveness ratio (ICER) and the incremental net-benefit
statistic, we base our assessment of agreement on the latter.
This is because of well-known issues surrounding the ICER
[12, 33] that makes it unsuitable as a statistic on which to
base assessment of agreement. For example, the sampling
distribution of the ICER is unknown, and it can be prob-
lematic to estimate associated measures of uncertainty.
Also, because the ICER is a ratio of incremental costs and
incremental effects, two ICERs can be equal in magnitude
but qualitatively different in meaning when they fall in
different quadrants of the cost-effectiveness plane. The
incremental net benefit statistic, on the other hand, is
unambiguous with relatively straightforward interpretation
and its sampling distribution is known at the specified cost-
effectiveness threshold [33].
The remainder of the paper is structured as follows:
‘‘Methods’’ outlines the proposed methodological frame-
work. In ‘‘Example application to the PiPS trial’’, we illus-
trate an application using data from a recently conducted
trial-based economic evaluation investigating the benefits of
early administration of the probiotic Bifidobacterium breve
strain BBG (B breve BBG) to prevent development of
infection (sepsis) in babies less than 31 weeks of gestation.
We present final concluding remarks in the ‘‘Discussion’’
section, including the potential implications of increasing
recourse to routinely collected data for the conduct of trial-
based economic evaluations.
Methods
This section outlines our framework for assessing agree-
ment between the mean incremental net (monetary) bene-
fits estimated from two sets of data on treatment costs and
effects for trial participants. Three commonly used statis-
tics are adapted for this purpose: (1) the mean difference;
(2) the probability estimate of miscoverage; and (3) the
concordance correlation coefficient [18] between two
estimates of the incremental net benefit. We define the
probability estimate of miscoverage as the proportion of
samples in simulated replication of trial data in which the
confidence limits for the mean incremental net benefit from
one data source, designated as test data, contain the mean
incremental net benefit estimated from the second data
source, designated as the referent or gold standard data
source. We outline a strategy for estimating the miscov-
erage probability and show how the concordance correla-
tion coefficient can be adapted for assessing agreement
between two estimates of the mean incremental net benefit
evaluated at a specified cost-effectiveness threshold. A
package to implement the routines described in the
remainder of the paper in [28] is available from https://
github.com/agaye/ceeComp.
F. Achana et al.
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Difference between two estimates of the incremental
net benefit
Consider a trial in which paired data on treatment costs and
effects, denoted as D1 and D2, are available for N trial par-
ticipants randomized to one of two interventions, denoted as
A and B. Our illustrative example in the section ‘‘Example
application to the PiPS trial’’ highlights two potential data
sources, namely trial case report forms and data obtained
from a national patient electronic system. Denote A as con-
trol intervention and let bik be an estimate of the mean
incremental net benefit of intervention B relative to A from
the ith dataset Di ði ¼ 1; 2Þ at a specified cost-effectiveness
threshold k. Then a simple measure of discrepancy between
the two estimates of cost-effectiveness (in the form of the
incremental net benefit of intervention B relative to A) gen-
erated from two data sources is xk where
xk ¼ b2k  b1k: ð1Þ
The variance of xk (after dropping the ks to simplify the
notation) is given by
r2x ¼ r2b1se þ r2b2se  2qb1se;b2se ; ð2Þ
where rb1se , rb2se represent standard error of the incremental
net benefit from datasets 1 and 2, respectively. Incremental
net benefits generated this way are likely to be correlated, as
the two datasets contain information from the same patients,
the parameter qb1se;b2se quantifies the covariance between the
two. The parameters x, b1, b2 and associated variance and
covariance terms in Eqs. (1) and (2) are unobserved, hence
will be replaced in practice with their sample counterparts x^,
b^1 and b^2, respectively.We show inAppendicesA andB that
the variance and covariance terms on the right hand side of
Eq. (2) can be written in terms of the variance of costs and
effects and the covariance between the two within the
respective arms of a trial with parallel group design (as-
suming no treatment switching or cross-over effects com-
mon in cancer trials). Under the large sample assumption, an
approximate statistical test of the null hypothesis that there is
no difference between incremental net benefits generated
from the two data sources (i.e.,x ¼ 0) can be constructed by
referring an estimate Z^ of the Z statistic to the standard
normal distribution where Z^ is given by
Z^ ¼ x^
r^x
: ð3Þ
Note that failure to reject the null hypothesis of no
agreement above does not imply evidence of agreement or
that the two incremental net benefits are equivalent. A
statistical test of equivalence if required can be constructed
by specifying an equivalence margin d followed by two
one-sided tests of the hypothesis that |x|\± d [38].
Probability of miscoverage
This section introduces the probability estimate of mis-
coverage as a statistic for assessing agreement between
two cost-effectiveness estimates. Miscoverage probabili-
ties have previously been used in the health economics
literature [27] to compare the performance of different
methods for estimating confidence intervals for the ICER.
However, unlike Polsky et al., we base our assessment on
the incremental net benefit rather than the ICER for the
reasons stated in the introduction. For any two data
sources that are available for the economic evaluation, we
first designate one data source as referent data and the
other as test data. From the referent dataset, we calculate
b^ref ;k, the sample estimate of the underlying population
mean incremental net benefit bref ;k at cost-effectiveness
threshold k. Next, we sample with replacement several
times to generate S bootstrap replicates of the test data.
For each replicate dataset, we calculate a bootstrap esti-
mate of the incremental net benefit and the associated
variance given by Eq. (9) of Appendix A. Finally, we
obtain the probability of miscoverage by counting the
proportion of the S bootstrap replicates in which the
(95%) confidence intervals for the incremental net benefit
statistic does not contain the corresponding estimate from
the referent dataset.
Concordance correlation
Lin [18] introduced the concordance correlation coeffi-
cient, qc and used it to quantify agreement or repro-
ducibility of a clinical assay, test, or measuring instrument
compared to the current measure or a gold standard. In
doing so, Lin [18–20] defined perfect agreement between
two measurements as a 45 line passing through the origin
of the Cartesian (X, Y) plane so that deviations from this
line indicate evidence of disagreement. The concordance
correlation coefficient quantifies this deviation in terms of
the precision and accuracy of the new measure compared to
the gold standard. As a correlation coefficient, qc satisfies
the inequality 1 qc  1 where qc ¼ 1 indicates perfect
agreement, qc ¼ 0 no agreement and qc ¼ 1 perfect
inverse agreement.
To adapt Lin’s method for our purpose, let
Dj1 ¼ Cj1;Ej1; tj
 
;Dj2 ¼ Cj2;Ej2; tj
  
denote again our
paired outcome information (comprising of treatment costs
Cjt and effects Ejt) for the jth patient (j ¼ 1; 2; . . .;N) in
treatment group tj ¼ A or B from a bivariate population
with mean incremental net monetary benefit ðb1; b2Þ and
variance ðr2b1 ; r2b2Þ at specified cost-effectiveness threshold.
Following Lin [18], the degree of concordance between
A methodological framework for assessing agreement between cost-effectiveness outcomes…
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incremental net-benefits generated from the two data
sources can be quantified by the expected value of the
squared difference on the incremental net benefit scale:
E½ðD2  D1Þ2 ¼ ðb2  b1Þ2 þ r2b1 þ r2b2  2qb1b2 : ð4Þ
where rb1 and rb2 represent standard deviation of incre-
mental net benefit generated from the twodatasets andqb1b2 are
the covariance between the two. Lin [18] showed that Eq. (4)
can be written in terms of the Pearson correlation coefficient q
which he suggested provided ameasure of precision (i.e., ‘‘how
far each observation deviates from the best fitted line’’) and a
bias correction factorCb that measures accuracy (i.e., ‘‘how far
the best fitted line deviates from the 45 line’’):
qc ¼ qCb where Cb ¼
2rb1rb2
ðb2  b1Þ2 þ r2b1 þ r2b2
:
when used to assess agreement between pairs of mea-
surements, an estimate q^c of qc is obtained by replacing the
parameters in Eq. (4) with their sample estimates. Hence,
in our adaptation of Lin’s method, we define q^c in terms of
the incremental net benefit generated from two data
sources:
q^c ¼
2q^b1;b2
ðb^2  b^1Þ2 þ r^2b1 þ r^2b2
; ð5Þ
where b^2 and b^1 represent sample estimates of the incre-
mental net benefit from the respective datasets, r^b1 and r^b2
represent estimates of the corresponding standard deviation
and q^b1;b2 estimate of the covariance between the two. Again
as shown inAppendicesA andB, the parameters on the right-
hand side of Eq. (5) can be written in terms of the arm-
specific estimates of the mean costs and effects given by
Eq. (6) and associated variance and covariance terms given
by Eqs. (9) and (16), respectively. Finally, to estimate a
confidence interval and carry out hypotheses tests, Lin [18]
suggested the Fisher Z transformation as a useful approxi-
mation to the standard normal distribution with mean
Zqc ¼
1
2
ln
1þ qc
1 qc
 
;
and variance r2Zqc : An estimate Zq^c and r
2
Zq^c
of Zqc and r
2
Zqc
can be obtained using bootstrapping before re-transforming
back to the original scale.
Statistical tests of the hypothesis that qc is greater than
an arbitrarily defined threshold value, qc0, can be con-
structed using the transformed parameters and one-sided
p values generated for a specified level of significance.
Concordance correlation coefficient thresholds often cited
in the literature as indicating acceptable levels of agree-
ment include qc0[ 0:4 [4] and qc0[ 0:65 [11] with
coefficients greater than 0.8 generally taken as good
evidence of agreement [11, 22]. Rather than define an
arbitrary threshold value, an alternative strategy suggested
by Lin [19] is to estimate qc0 through the expression qc0 ¼
Cb
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
q2  x
p
where x represents a pre-specified percentage
loss in precision that is acceptable for the particular mea-
sure or clinical scenario under investigation and q is again
the Pearson correlation coefficient. For example, x ¼ 0:05
for a 5% acceptable loss in precision. In our adaptation of
this approach, if we designate one dataset as the referent
data and another as the test dataset, then x represents the
percentage loss in precision in mean incremental net
monetary benefit generated from the test data that can be
considered acceptable compared with the corresponding
estimate obtained using the referent dataset. Statistical tests
of the hypothesis that qc[ qc0 can then be constructed and
one-sided p-values estimated.
Example application to the PiPS trial
Example data
TheProbiotic inPretermbabiesStudy (PiPS) is amulti-center,
double-blind, placebo-controlled randomized trial of probi-
otic administration in infants born between 23?0 and 30?6
weeks gestational age. The trial recruited 1300 infants within
48 h of birth from24hospitalswithin 60miles ofLondon over
a 37-month period from July 2010 onwards. Infants were
randomized to receive either the probiotic Bifidobacterium
breve BBG-001 or a matching placebo. Details of the trial
design and baseline characteristics of trial participants are
published elsewhere [7]. The main trial analyses and findings
have also been published [6]. The main trial economic eval-
uation has not yet been published, so a summary of the
methods used to conduct the evaluation is presented in Ap-
pendix C. For the purpose of illustrating the methodology
described in this paper, we restrict ourselves to 1258 of the
1300 infants who had complete data on treatment costs and
clinical outcomes of interest. Of these, 638 infants were in the
placebo group and 620 in the probiotic group. Three clinical
outcomes were considered in the trial: (1) any episode of
neonatal necrotizing enterocolitis (NEC) Bell stage 2 or 3 [2];
(2) any positive blood culture of an organism not recognized
as a skin commensal on a sample drawn more than 72 h after
birth and before 46 weeks postmenstrual age or discharge if
sooner (hereafter referred to as sepsis for brevity); and (3)
death before discharge from hospital. We restrict ourselves to
the sepsis outcome for the purpose of illustrating the
methodological framework described in this paper.
Data on PiPS trial participants were available from two
primary sources, the trial case report forms and the
National Neonatal Research Database (NNRD) (The
F. Achana et al.
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Neonatal Data Analysis Unit [34]. The PiPS trial case
report forms captured a comprehensive profile of resource
use by each infant, encompassing length of stay by inten-
sity of care, surgeries, investigations, procedures, transfers
and post-mortem examinations until final hospital dis-
charge or death (whichever was earliest). Resource inputs
were primarily valued based on data collated from sec-
ondary national tariff sets [8]. All costs were expressed in
pounds sterling and reflected values for the financial year
2012–13. The trial case report forms also captured infor-
mation on the clinical outcomes of interest. The NNRD has
been created through the collaborative efforts of neonatal
services across the UK to be a national resource. The
NNRD contains a defined set of data items (the Neonatal
Dataset) that have been extracted from the Badger.net
neonatal electronic patient record of all admissions to
National Health Service (NHS) neonatal units. Badger.net
is managed by Clevermed Ltd, an authorized NHS hosting
company. The Neonatal Dataset is an approved NHS
Information Standard (ISB1575) and contributing neonatal
units are known as the UK Neonatal Collaborative.
Our comparisons of cost-effectiveness outcomes were
based on four datasets that we created using information
from the two primary data sources: (1) the trial case report
forms as the sole source of information (hence forth
referred to as PiPS dataset); (2) the NNRD as the source of
information on resource inputs only with clinical outcomes
extracted from the PiPS case report forms (herein referred
to as the NNRD1 dataset); (3) the NNRD as a source of
resource use and clinical outcomes (herein referred to as
the NNRD2 dataset); and (4) a combined dataset created by
the selection of a preferred data source (by clinical experts)
for each data input.
Results
Table 1 presents descriptive summaries of the cost-effec-
tiveness estimates for the probiotic compared to placebo,
obtained from each of the four datasets described above.
Based on the data from the trial case report forms (PiPS
dataset), the proportion of infants with sepsis and the mean
total cost were 10.8% and £62,799, respectively, in the
probiotic group, compared with 11.3% and £62,284 in the
placebo group, generating a mean absolute incremental
effect of 0.50%, mean incremental costs of £515, and an
ICER of £107,613 per episode of sepsis averted. As stated
above, the trial case report forms also served as the primary
source of clinical outcome information for the NNRD1 and
the combined datasets, thus these two datasets differed
from the PiPS dataset only in terms of healthcare utilization
data and hence treatment costs. For these (NNRD1 and the
combined) datasets, the probiotic was associated with
slightly lower total healthcare costs than placebo, gener-
ating a mean cost saving of £367 in the NNRD1 dataset and
£342 in the combined datasets. Thus, on average, the
probiotic dominated placebo in health economic terms in
these two datasets. Finally, the NNRD2 dataset indicated
that the probiotic is less effective and less costly, on
average, than placebo, generating a mean ICER of
£111,348 per episode of sepsis averted for the probiotic
compared with placebo. Overall, although the PiPS and
NNRD2 datasets generated mean ICERs that are very
similar in magnitude, they have different interpretations
because the mean ICER for the PiPS dataset occupies the
north-east quadrant of the cost-effectiveness plane, sug-
gesting that the probiotic is more costly and more effective
than placebo, whereas the mean ICER for the NND2
Table 1 Cost-effectiveness results from the PiPS trial datasets
Dataseta Placebo arm Probiotic arm Cost-effectiveness
Costs (£) Outcomeb Costs (£) Outcomeb Incremental costs (95%
confidence interval)c
Incremental effects (95%
confidence interval)d
ICER
PiPS 62,284 (1876) 0.113 (0.013) 62,799 (1817) 0.108 (0.013) 515 (-4603, 5633) 0.005 (-0.03, 0.039) 107,613
NNRD1 60,927 (1805) 0.113 (0.013) 60,560 (1571) 0.108 (0.013) -367 (-5058, 4323) 0.005 (-0.03, 0.039) -76,662
NNRD2 60,927 (1805) 0.058 (0.009) 60,560 (1571) 0.061 (0.010) -367 (-5058, 4323) -0.003 (-0.029, 0.023) 111,348
Combined 60,796 (1799) 0.113 (0.013) 60,454 (1566) 0.108 (0.013) -342 (-5016, 4332) 0.005 (-0.03, 0.039) -71,422
PiPS dataset trial case report forms as the sole source of information, NNRD1 dataset NNRD as the source of information on resource inputs only
with clinical outcomes extracted from the PiPS case report forms, NNRD2 dataset NNRD as a source of resource use and clinical outcomes,
Combined dataset combined dataset created by the selection of a preferred data source (by clinical experts) for each data input
a Datasets
b Outcome = proportion of sepsis
c Incremental costs (£) is defined as mean costs in probiotic arm minus mean costs in placebo arm
d Incremental effects is proportion of sepsis avoided, hence effectiveness differential is reversed (i.e., mean effect in placebo arm minus mean
effect in the probiotic arm) because the outcome is an adverse event
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dataset occupies the south-west quadrant where the probi-
otic is less costly but also less effective (Fig. 1). The mean
ICERs from three of the four datasets fell in a different
quadrant of the cost-effectiveness plane, but a large pro-
portion of the simulated ICERs from each dataset fell in all
four quadrants, reflecting the considerable uncertainty
surrounding the mean ICERs. Figure 1 illustrates the point
made in the introduction that the ICER may not be an
appropriate statistic for assessing agreement between esti-
mates of cost-effectiveness generated from alternative data
sources. Cost-effectiveness acceptability curves based on
three of the four datasets indicates the probiotic is the most
cost-effective strategy for sepsis prevention in pre-term
infants with probability of 0.6 but only at considerably high
cost-effectiveness thresholds (upwards of £80,000 per
sepsis avoided) whilst the probiotic is dominated by pla-
cebo in the NNRD2 dataset (Fig. 2). Overall, the results
suggest the probiotic is not cost-effective unless policy
makers are willing to spend large amounts of money to
prevent infants from developing sepsis.
Table 2 presents the agreement statistics (mean differ-
ence, probability estimates of miscoverage and
concordance correlation coefficients) between estimates of
the mean incremental net benefit from combinations of the
four alternative datasets using a cost-effectiveness thresh-
old of £30,000 per episode of sepsis avoided. At this
threshold, the probability estimate of miscoverage was very
small, ranging from 3.9% when the combined dataset acted
as referent source and the NNRD1 acted as the test data to
6.0% when the PiPS dataset acted as referent and the
NNRD2 as the test data. The corresponding p values ran-
ged from 0.387 for the comparison between the PiPS ver-
sus NNRD1 datasets to 0.634 for the comparison between
the PiPS versus NNRD2 datasets. These results thus pro-
vide no evidence to suggest that the incremental net benefit
estimated using one dataset is significantly different from
the incremental net benefit estimated from the other data-
sets at a cost-effectiveness threshold of £30,000 per epi-
sode of sepsis avoided.
Agreement between mean incremental net benefit
statistics from alternative datasets as measured by the
concordance correlation coefficient ranged from a corre-
lation coefficient of 0.882 (95% CI 0.870–0.893) for the
comparison between the PiPS and the NNRD1 datasets to a
Fig. 1 PIPS trial ICERs from the four datasets comparing probiotic
versus placebo for prevention of sepsis in newborn infants displayed
on the cost-effectiveness plane. NNRD1 dataset acted as source of
resource use information only. NNRD2 acted as source of both
resource use and clinical outcome information
F. Achana et al.
123
coefficient of 1 indicating perfect correlation for the
comparison between the combined and the NNRD1 data-
sets at the £30,000 per episode of sepsis avoided threshold.
These correlation coefficients are well above the com-
monly cited threshold of 0.4 commonly taken as indicating
evidence of good agreement [4]. The alternative strategy is
to define a threshold based on percentage loss in precision
that is acceptable for the clinical issue being investigated.
Estimates of qc0 based on a 5% loss in precision criterion
ranged from 0.856 for the PiPS versus NNRD2 comparison
to 0.975 for the combined versus NNRD1 comparison.
These values of qc0 were significantly lower than the lower
confidence limit for qc (p\ 0.0001) in each pairwise
comparison (Table 2), indicating stronger evidence of
agreement between datasets.
Estimates of the agreement statistics at cost-effective-
ness thresholds between £0 and £500,000 per episode of
sepsis avoided were also generated and can be read off the
plots in Fig. 3. The p values remained relatively constant
across different values of k for pairwise comparisons
between the PiPS, NNRD1, NNRD2, and the combined
datasets. Although no attempt was made to correct for
multiple testing at different thresholds, this can easily be
achieved by for example, defining a statistical significance
at the 1% level instead of the 5% level [36]. Overall, across
cost-effectiveness thresholds ranging from £0 to £500,000
per sepsis avoided and for all pairwise comparisons
between datasets, differences between mean incremental
net benefits were not statistically significant (p values
C0.4), the probability estimates of miscoverage fell within
the interval (0.025–0.075) and concordance correlation
coefficient were greater than 0.5.
Discussion
In this paper, we have shown how three commonly used
metrics (namely difference in mean, miscoverage proba-
bility, and the concordance correlation coefficient) can be
adapted and used to assess agreement between the final
economic endpoints generated from alternative sources of
data on costs and effects within the context of trial-based
Fig. 2 Cost-effectiveness acceptability curves indicating probability
at which the probiotic is cost-effective compared with placebo for a
range of cost-effectiveness or willingness-to-pay thresholds
Table 2 Statistics comparing the agreement between cost-effectiveness estimates from the PiPS trial datasets
Comparison
quadrant
Agreement statistics
Difference in means Probability of
miscoverage
Concordance correlation
Dataset 1 Dataset
2
Mean INB
(std. err) from
dataset 1
Mean INB
(std. err) from
dataset 2
MD (SE) p value qc (95% CI) qc0
a p value
PiPS NNRD1 -372 (2808) 511 (2596) 882 (1021) 0.387 0.060 0.882 (0.870, 0.893) 0.856 \0.001
PiPS NNRD2 -372 (2808) 268 (2520) 640 (1129) 0.571 0.051 0.885 (0.874, 0.895) 0.858 \0.001
NNRD1 NNRD2 511 (2596) 268 (2520) -243 (454) 0.593 0.041 0.980 (0.977, 0.982) 0.954 \0.001
Combined PiPS 486 (2588) -372 (2808) -857 (1021) 0.401 0.049 0.884 (0.872, 0.895) 0.858 \0.001
Combined NNRD1 486 (2588) 511 (2596) 25 (44) 0.565 0.046 1.000 (1.000, 1.000) 0.974 \0.001
Combined NNRD2 486 (2588) 268 (2520) -217 (457) 0.634 0.039 0.980 (0.978, 0.983) 0.955 \0.001
INB incremental net benefit evaluated at willingness-to-pay threshold of £30,000 per adverse event averted, Std. err. Standard error of the
estimate, MD difference between mean INB from dataset 1 and mean INB from dataset 2, qc (95% CI) concordance correlation coefficient (95%
confidence intervals) between the incremental net benefits at threshold of £30,000 per adverse event averted
 Two-sided p value at 5% significance level
 The first dataset in each pairwise comparison is designated as referent when estimating the probability of miscoverage
p value One-sided test of the hypothesis that qc[qc0 where qc0 is the least acceptable concordance correlation coefficient assuming 5% (qc0
a).
A p value greater than 0.025 suggests significant evidence of disagreement at the at the 5% significance level
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economic evaluations. Agreement statistics are obtained
for a range of cost-effectiveness thresholds and plotted on
simple graphs to ease comparability. Application of the
method to data from the PiPS trial datasets revealed no
evidence of disagreement, low probability levels of mis-
coverage, and high concordance correlation between esti-
mates of incremental net monetary benefit generated using
data from trial case report forms and data from the NNRD
dataset.
Assessment of agreement in the health economics lit-
erature [4, 21, 23] have thus far focused on comparisons
between alternative sources of resource use and cost vari-
ables, primarily because healthcare utilization data can and
has often been collected from a multitude of sources such
as patient self-reports, medical records, and trial case report
forms. Data on clinical endpoints have, however, tended to
come from a single source, often the trial case report forms.
With recent advances in data management and information
sciences, routine datasets are increasingly being compiled
that have potential to provide patient-level resource uti-
lization and clinical outcomes data for trial-based eco-
nomic evaluations. As these potentially rich sources of data
become available for clinical research, methods for
assessing the level of agreement between final cost-effec-
tiveness outcomes (of interest in the trial-based economic
evaluations) generated using alternate sources of data will
be of interest to analysts working on health economic
evaluations and health technology assessments. We have
shown how such assessments can be carried out in practice
using the PiPS trial data. Our preliminary analyses show
the NNRD database could potentially serve as a reliable
source of data on treatment costs and effects for future
trial-based economic evaluations of neonatal interventions.
Application to other trial-based economic evaluations
where the NNRD has been used as a source of data would
allow the potential of this resource to be explored for trial-
based economic evaluations.
The methodology outlined in this paper is based on the
incremental monetary net benefit statistic as the final eco-
nomic endpoint of interest in the economic evaluations.
This enabled the joint endpoints of clinical outcome and
cost to be transformed to a univariate scale whilst
accounting for the correlations between patient-level costs
and effects between datasets. The transformation also
allows for assessment of agreement to be conducted when
costs and outcomes are measured on different scales (for
example where cost is a continuous variable and the clin-
ical outcome is binary as is the case in our illustrative
example). Rather than transforming costs and health out-
comes to the same scale, an alternative and potentially
Fig. 3 Two-sided p values, probability estimates of miscoverage and
concordance correlation coefficients for comparing the agreement
between cost-effectiveness estimates from the PiPS, NNRD, and
combined data sources. NNRD1 dataset acted as source of resource
use information only. NNRD2 acted as source of both resource use
and clinical outcome information
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more attractive strategy would be to assess the agreement
between observed resource use and clinical outcome vari-
ables when multiple sources of healthcare utilization and
clinical outcome data are available. This is similar to
assessment of agreement between measurements of a
multivariate response such as blood pressure measurements
with two pressure readings (diastolic and diastolic), and
repeated measurements where outcomes are measured over
time. Methods have been proposed in the literature
extending the approach by Lin [18] to assessment of
agreement of more complex data structures such as repe-
ated measurement problems and multivariate response
variables measured on the continues scale [5, 14, 16, 17].
These methods can, in principle, be adapted for assessment
of agreement between two sources of data on treatment
costs and effects. We have not however done so in our
study because whilst healthcare costs are measured on the
continuous scale, the clinical endpoint of interest in the
PiPS trial example that serves to motivate our approach is a
binary outcome (i.e., whether or not an infant avoids an
episode of sepsis). It is not immediately obvious how to
adapt these multivariate techniques for assessing agree-
ment between outcomes measured on different scales.
Further methodological work exploring the feasibility of
assessing agreement involving multivariate mixed out-
comes where the outcomes measured are of different data
types and measured on different scales would present a
useful advancement of the methodology presented here.
Our methodological framework assumes that the cost-
effectiveness threshold is not kinked despite evidence from
O’Brien et al. [25] that a kinked threshold better reflects
asymmetrical individual preferences found in empirical
studies of consumer’s willingness to pay for health chan-
ges, which would in turn justify different decision rules in
the north-east and south-west quadrants of the cost-effec-
tiveness plane [10]. Further research is required to assess
how the methodological framework presented here might
be extended in the presence of a kinked cost-effectiveness
threshold.
Finally, how might the approach outlined above be used
in practice? Our goal in this paper is to develop a
methodology for assessing the level of agreement between
the final economic endpoints of interest in trial-based
economic evaluations. The method should not be applied
directly to economic evaluations based on observational
data or alongside other non-randomized study designs as
the results of such analyses could be biased by the lack of
randomization. This can propagate into biased estimates of
agreement. Further work is required to develop methods
that allow the level of agreement between cost-effective-
ness outcomes to be assessed whilst appropriately
accounting for potential imbalances in the distribution of
confounding factors between the treatments being com-
pared in the economic evaluation.
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Appendix A: variance of the incremental net
(monetary) benefit
To derive the variance of the difference between two
incremental net monetary benefits, we first derive the
variance of the net benefit in terms of variances and
covariances between costs and effects within trial arms. Let
CA, EA, rCA ,rEA and qCAEA represent population level
estimates of the mean costs, mean effects, standard devi-
ation of costs, standard deviation of effects and covariance
between costs and effects in intervention arm A (taken as
control). We have CB, EB, rCB ,rEB and qCBEB as the cor-
responding quantities in intervention arm B, respectively.
By definition of the incremental net benefit at a specified
cost-effectiveness threshold, k, we have
bk ¼ kDE  DC ¼ kðEB  EAÞ  ðCB  CAÞ: ð6Þ
Taken variances of both sides of Eq. (6), we have
varðbkÞ¼ k2varðDEÞþvarðDCÞ2kcovðDE;DCÞ
¼ k2varðEBEAÞþvarðCBCAÞ2k½ðEBEAÞ;
ðCBCAÞ: ð7Þ
The variance terms on the right hand side of Eq. (7) are
given by varðEB  EAÞ ¼ r2EB þ r2EA and varðCB  CAÞ ¼
r2CB þ r2CA , and the covariance term by
cov[ðEBEAÞ; ðCBCAÞ ¼ cov(EB;CBÞ cov(EB;CAÞ
 cov(EA;CBÞþ cov(EA;CAÞ
¼ cov(EB;CBÞþ cov(EA;CAÞ
¼ qEACA þqEBCB :
ð8Þ
A methodological framework for assessing agreement between cost-effectiveness outcomes…
123
The two middle terms on the right hand side of the first
line of Eq. (8) are zero because treatment arms in trials
with a parallel-group design (i.e., no treatment switching or
cross-over effects) are independent. Substituting the
expressions for the variance and covariance terms derived
in Eq. (8) into Eq. (7) gives the variance of the incremental
net benefit in terms of the arm-specific variances and
covariances between costs and effects:
varðbkÞ ¼ k2ðr2EB þ r2EAÞ þ ðr2CB þ r2CAÞ  2kðqEACA
þ qEBCBÞ: ð9Þ
Appendix B: Covariance between two incremental
net (monetary) benefits
The variance of the difference between two incremental net
benefits is derived by taking variances of both sides of the
expression xk ¼ b2k  b1k given by Eq. (1):
varðxkÞ ¼ varðb1kÞ þ varðb2kÞ  2covðb1k; b2kÞ: ð10Þ
The variance terms on the right-hand side of Eq. (10)
are given by Eq. (9) for the ith dataset (i = 1, 2), so all we
need is an expression for the covariance term covðb1k; b2kÞ.
Now from the definition of the incremental net benefit (6),
we have
cov(b1k; b2kÞ ¼ cov½ðkDE1  DC1Þ; ðkDE2  DC2Þ
¼ cov(kDE1; kDE2Þ  cov(kDE1;DC2Þ
 cov(kDE2;DC1Þ þ cov(DC1;DC2Þ:
ð11Þ
The first term on the right-hand side of Eq. (11) is
cov kDE1; kDE2ð Þ ¼ cov kðE1B  E1AÞ; kðE2B  E2AÞ½ 
¼ k2ðcov(E1B;E2BÞ  cov(E1B;E2AÞ
¼ k2ðcov(E1B;E2BÞ þ cov(E1A;E2AÞÞ
¼ k2ðqE1AE2A þ qE1BE2BÞ:
ð12Þ
The remaining terms on the right-hand side of Eq. (11)
can be derived in a similar manner:
cov(kDE1;DC2Þ ¼ cov kðE1B  E1AÞ; ðC2B  C2AÞ½ 
¼ cov(kE1B;C2BÞ  cov(kE1B;C2AÞ
 cov(kE1A;C2BÞ þ cov(kE1A;C2AÞ
¼ cov(kE1B;C2BÞ þ cov(kE1A;C2AÞ
¼ kðqE1AC2A þ qE1BC2BÞ:
ð13Þ
covðkDE2;DC1Þ ¼ kðqE2AC1A þ qE2BC1BÞ; ð14Þ
cov(DC2;DC1Þ ¼ qC2AC1A þ qC2BC1B : ð15Þ
Substituting the results of Eqs. (12)–(15) into Eq. (11)
gives Eq. (16) as the covariance between two incremental
net (monetary) benefits evaluated at a cost-effectiveness
threshold, k:
cov(b1k; b2kÞ ¼ k2ðqE1AE2A þ qE1BE2BÞ  kðqE1AC2A
þ qE1BC2BÞ  kðqE2AC1A þ qE2BC1BÞþ ðqC2AC1A þ qC2BC1BÞ: ð16Þ
When carrying out the analysis in practice, all parame-
ters in Eqs. (6)–(16) are replaced with their sample coun-
terparts C^A, E^A, r^CA ,r^EA and q^CA;EA in arm A and C^B, E^A,
r^CB ,r^EB and q^CB;EB in arm B. The square of the standard
error of the incremental net benefits in equation (2) are
obtained by dividing the arm-specific variance and
covariance terms on the right hand side of Eqs. (6)–(16) by
NA and NB, the number of individuals in treatment arms
A and B respectively.
Appendix C: methods of the PiPS trial economic
evaluation
Study population
Probiotics in Preterm Infants Study (PIPS) trial
Probiotics in Preterm Infants Study (PIPS) was a multi-
center blinded randomized placebo-controlled trial
designed to test the effectiveness of the probiotic Bifi-
dobacterium breve BBG-001 to reduce NEC, late-onset
sepsis, and death in preterm infants. Infants born between
23 weeks and 0 days and 30 weeks and 6 days of gesta-
tion with written parental consent were eligible for
recruitment.
The National Neonatal Research Database (NNRD)
The National Neonatal Research Database (NNRD) has
been created through the collaborative efforts of
neonatal services across the country to be a national
resource. The NNRD contains a defined set of data items
(the Neonatal Dataset) that have been extracted from the
Badger.net neonatal electronic health record of all
admissions to NHS neonatal units. Badger.net is man-
aged by Clevermed Ltd, an authorized NHS hosting
company. The Neonatal Dataset is an approved NHS
Information Standard (ISB1575). Contributing neonatal
units are known as the UK Neonatal Collaborative.
Variables that allowed for the creation of comparable
resource use Items (directly available or derivable) were
extracted from the NNRD
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Combined dataset
An additional dataset was created by selecting a variable
from either PIPS or NNRD that represented a resource use
item more accurately.
For the purposes of our study, only those infants were
analyzed for whom there was data available from both the
PIPS trial and the NNRD.
Type of economic evaluation, study perspective,
and time horizon
The economic evaluation took the form of a cost-effec-
tiveness analysis in which we estimated the incremental
costs (DC) and incremental effects (DE) attributable to
probiotic (B breve BBG) in preterm infants, with reference
to a placebo, and expressed each in terms of an incremental
cost-effectiveness ratio (ICER; DC/DE). Estimates of cost-
effectiveness were made for the three primary clinical out-
comes (any episode of NEC, any case of Sepsis, death
before discharge from hospital), and for one secondary
outcome, which was a composite of the three primary out-
comes. The economic evaluation was conducted from a
health system perspective and consequently only direct costs
to the NHS were included [24]. The time horizon of the
study was birth to discharge or death, whichever was earlier.
Measurement of resource use and costs
Relevant resource items were integrated into the trial data
collection instruments described previously. The neonatal
and maternal data collection forms captured a compre-
hensive profile of resource use by each infant, encom-
passing length of stay by intensity of care, surgeries,
investigations, procedures, transfers, and post-mortem
examinations until final hospital discharge or death
(whichever was earliest). Variables that allowed for com-
parison of selected resource use items in the PIPS data
directly or through derivation were extracted from the
NNRD. Resource inputs were valued based on data col-
lated from secondary national tariff sets [8, 9]. All costs
were expressed in pounds sterling and reflected values for
the financial year 2012–13.
The total length of stay (total inpatient hospital days)
was computed as the total number of hospital days until
first discharge to home or death. Postnatal costs for the
mothers were based on the method of delivery available in
the data source and costs assigned using data from the NHS
Reference Costs trusts schedule 2012/13 [9]. Information
was available on time spent in the neonatal unit by level of
care (normal, transitional, special, high dependency or
intensive), by varying level of detail from both data sour-
ces. The cost of neonatal care was calculated for each
infant by multiplying the length of stay in normal care
(where available), transitional care (where available),
special care, high dependency care, or intensive care by the
per diem cost of the respective level of care using data
from the NHS Reference Costs trusts schedule 2012/13 [9].
The costs of surgeries and procedures were calculated by
assignment of surgical procedures to relevant Healthcare
Resource Group (HRG) codes and application of unit costs
from national tariffs [9]. Transfers were recorded whenever
an infant was transported between specialist hospitals for
neonatal critical care, and were valued using costs from the
NHS Reference Costs trusts schedule 2010/11 [9]. Post-
mortem costs were based on data from secondary sources
[30]. Non-routine investigations excluded from these per
diem costs were valued using a combination of primary and
secondary costs. Where these costs were not available from
national tariffs, clinicians were asked to identify the staff
and material inputs required for these investigations. Staff
time was valued using the Unit Costs of Health and Social
Care tariffs [8].
Cost-effectiveness analytical methods
Neonatal characteristics and resource use items were
summarized by trial arm (placebo or B. breve BBG). Dif-
ferences between groups were analyzed using t tests for
continuous variables and v2 test for categorical variables.
Mean (standard error (SE) costs by cost category and mean
(SE) total costs were estimated by trial arm and compar-
isons were carried out using Student’s t tests.
Cost effectiveness was expressed as incremental cost per
(1) adverse perinatal outcome avoided. Nonparametric
bootstrapping, involving 1000 bias-corrected replications
of each of the incremental cost effectiveness ratios, was
used to calculate uncertainty around all cost-effectiveness
estimates [35]. This was represented on four quadrant cost-
effectiveness planes. Decision uncertainty was addressed
by estimating net benefit statistics and constructing cost-
effectiveness acceptability curves across cost-effectiveness
threshold values of between £0 and £70,000 for the health
outcomes of interest. A series of sub-group analyses
repeated all analyses by selected sub-groups for the pri-
mary and secondary cost-effectiveness outcomes. All
analyses were estimated using Stata version 12 [32] and R
version 2.01 [28].
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